Noro Polymerase and Protease Inhibitors

Program Discovery Preclinical Phase 1 Phase 2a Phase 3
Norovirus (Gastroenteritis) Replication and Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started

We continue to identify and develop non-nucleoside polymerase inhibitors using the Company’s proprietary structure-based drug design technology platform. Cocrystal recently entered into a License Agreement with the Kansas State University Research Foundation to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections. Preclinical activities for our Norovirus program are currently under way. The Company expects to complete its proof-of-concept animal model study in the fourth quarter of 2020.